The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2023 | Ultra-sensitive and specific ctDNA assay for early stage lung cancer
James R. Black, MD, UCL, London, UK, discusses the development of NeXT Personal, a whole genome-based, tumor-informed assay for ultra-sensitive and highly specific circulating tumor DNA (ctDNA) detection. Pre-operative plasma samples from an interim cohort of patients with early-stage lung cancer from the TRACERx (NCT01888601) study were analyzed. ctDNA was detected in 81% of lung adenocarcinoma (LUAD) patients and in 100% of non-LUAD patients. Elevated pre-operative ctDNA levels correlated with poor overall survival and relapse-free survival (RFS) in LUAD patients, and correlated with reduced RFS in non-LUAD patients. It is concluded that the platform provides superior analytic performance and prognostic prediction compared to other clinically-validated assays in non-small cell lung cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
